info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)

Alpha-1 Antitrypsin Deficiency Treatment Market is expected to rise at a CAGR of 10.9% during 2022 – 2030

Pune, India, September 2022, MRFR Press Release/- Market Research Future has Published a Half-Cooked Research Report on the Global Alpha-1 Antitrypsin Deficiency Treatment Market.


Market Forecast


Registering a CAGR of 10.9%, the Global Alpha-1 Antitrypsin Deficiency Treatment Market is expected to extend USD 3.4 Billion by 2030.


As of July 2019, 3.4 million people are affected by alpha-1 antitrypsin deficiency worldwide. The disorder is found to affect populations in all the regions of the world.


The market is dominated by numerous established players. The key players are involved in product launches, strategic collaborations, and awareness programs to strengthen their market positions. For instance, in November 2018, Grifols S. A. launched the AlfaCare therapy program for training and counseling of patients diagnosed with alpha-1 antitrypsin deficiency.


Market Influencer


The prevalence of alpha-1 antitrypsin deficiency (AATD) is increasing, which is directly responsible for the growth of the global alpha-1 antitrypsin deficiency treatment market. Strategic initiatives, mergers & acquisitions, partnerships, agreements, product launches, government approvals, and expansion of manufacturing facilities by major competitors are expected to further boost market growth during the forecast period.


Global Alpha-1 Antitrypsin Deficiency Treatment Market Segmentation


By Drugs:



  • Alpha-1 Proteinase Inhibitor: The segment is expected to hold the largest market share as it is the only treatment for AATD, which protects the patient from more lung damage.

  • Bronchodilators: These are used for the treatment of respiratory disorders associated with AATD.

  • Steroids: These are used specifically for the treatment of chronic obstructive pulmonary disease, which affects the patient along with AATD.

  • Others: Other treatment options include antibiotics for infections and jaundice associated with AATD and oxygen therapy.


By Route of Administration:



  • Oral: The segment is expected to hold the largest market share.

  • Intravenous: The segment is expected to grow at the fastest CAGR.

  • Inhalation: This route of administration is used specifically for the administration of corticosteroids for treating breathing disorders.

  • Others: Subcutaneous and intramuscular routes of administration.


By Distribution Channel:



  • Hospital Pharmacy: The rise in the number of hospitals is likely to be responsible for the largest market size.

  • Retail Pharmacy: These fulfill the requirement of drugs that are needed for treatment at home.

  • Online Stores: The fastest-growing segment owing to increase in number of online pharmacies.


Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Alpha-1 Antitrypsin Deficiency Treatment Market Research Report


By Region



  • Americas: The region holds the largest share of the market. The market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.



  • Europe: The European alpha-1 antitrypsin deficiency treatment market has been classified as Western Europe and Eastern Europe. The Western European market has further been categorized as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.



  • Asia-Pacific: The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Asia-Pacific alpha-1 antitrypsin deficiency treatment market is projected to be the fastest-growing during the forecast period.



  • Middle East & Africa: The market in the Middle East & Africa has been divided into the Middle East and Africa.


Key Players



  • Kamada Pharmaceuticals (Israel)

  • CSL Behring LLC (US)

  • Grifols, S.A. (Spain)

  • Takeda Pharmaceutical Company Limited (Japan)

  • GlaxoSmithKline plc (UK)

  • Boehringer Ingelheim GmbH (Germany)

  • AstraZeneca (UK)

  • Vectura Group plc (UK)

  • Pfizer Inc. (US)

  • Mylan Inc. (US)

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Report details
Base Year 2022
Companies Covered 15
Pages 111
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.